Lyvgen Biopharma of Shanghai raised $30 million in a B round that was led by 6 Dimensions Capital. Founded in 2016, Lyvgen uses its xLinkAb technology platform to discover immune-oncology candidates. Its early-stage antibody pipeline includes a PD-1 candidate that it has out-licensed to Anhui Anke Biotech along with a set of proprietary co-stimulation agonist antibodies that Lyvgen believes could become first-in-class and best-in-class biotherapeutics.
Source: China Biotoday